Goldman Sachs set a GBX 3,750 ($52.30) target price on AstraZeneca (LON:AZN) in a research note published on Tuesday. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.

AZN has been the topic of a number of other research reports. Credit Suisse Group reissued an outperform rating and set a GBX 5,800 ($80.89) price objective on shares of AstraZeneca in a report on Tuesday, February 20th. JPMorgan Chase reissued an overweight rating and set a GBX 5,500 ($76.71) price objective on shares of AstraZeneca in a report on Tuesday. Shore Capital reissued a hold rating on shares of AstraZeneca in a report on Tuesday, April 3rd. UBS reissued a neutral rating on shares of AstraZeneca in a report on Monday, January 15th. Finally, Citigroup reissued a buy rating and set a GBX 6,200 ($86.47) price objective on shares of AstraZeneca in a report on Thursday, March 1st. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. AstraZeneca currently has an average rating of Hold and a consensus target price of GBX 5,234.04 ($73.00).

AZN stock opened at GBX 5,083 ($70.89) on Tuesday. AstraZeneca has a 52 week low of GBX 4,260 ($59.41) and a 52 week high of GBX 5,520 ($76.99).

In other news, insider Philip A. J. Broadley acquired 415 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was acquired at an average price of GBX 4,846 ($67.59) per share, with a total value of £20,110.90 ($28,048.68).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.